High Glycaemic Variability is Associated with Worse Diabetes-related Well-being in Type 2 Diabetes Patients on Insulin Therapy, an Observational Study
Journal Title: International Journal of Diabetes and Clinical Research - Year 2016, Vol 3, Issue 1
Abstract
Aims:Patients with diabetes have a reduced quality of life, especially those with high HbA1c. This study investigates if high glycaemic variability also negatively influences diabetes-related well-being. Methods:This cross-sectional observational study was conducted at the University Medical Centre Utrecht (UMCU), the Netherlands (February 2010-July 2013). Type 2 diabetes patients attending the (outpatient) clinic of the UMCU were approached to participate in a nationwide biobank study. In the UMCU, patients were also approached to participate in a local add-on study (this study), which required separate consent. Glycaemic variability was measured by continuous glucose monitoring in 124 patients with type 2 diabetes by standard deviation of glucose data from 48 hours. The Problem Areas in Diabetes Scale (PAID) was used to assess diabetes distress. Health status was assessed by 12-item short-form general health survey and EuroQaulity of life-5 dimensions visual analogue scale. Association of glycaemic variability and quality of life was analysed in the entire study population and in pre-defined subgroups (insulin treatment (n = 68); other treatment (n = 56)). Associations were investigated using linear regression. Results:A higher glycaemic variability tended to be associated (p = 0.07) with a worse PAID score in the entire study population (β0.20 (95% CI-0-01-0.42)), but this attenuated when adjusted for confounders. High glycaemic variability was associated with worse PAID score in insulin-treated patients (β0.33 (95% CI 0.01-0.65)), especially in the domains treatment-related problems (β0.29 (95% CI 0.09-0.50)) and diabetes-related emotional problems (β0.32 (95% CI 0.03-0.61)). These associations attenuated (β0.24 (95% CI 0.04-0.44); β0.24 (95% CI -0.06-0.54)) after correction for confounders and after correction for HbA1c (β0.15 (95% CI-0.07-0.38); β0.17 (95% CI-0.17-0.52)). Glycaemic variability was not consistently associated with parameters from other questionnaires. Conclusions:High glycaemic variability was associated with diabetes distress albeit not independent of HbA1c. Since this association was found in insulin-treated type 2 diabetes patients only; glycaemic variability could be a potential treatment goal for this particular group.
Hba1c Variability, Absolute Changes in Hba1c, and the Risk of Poor Glycemic Control among Older Adults with Diabetes Enrolled in Medicare Advantage Plans
Objective: To evaluate association of visit-to-visit HbA1c variability and absolute changes in HbA1c with poor glycemic control in patients with diabetes. Study design: A retrospective cohort study. Methods: Healthcare...
The Impact of Energy Drink Consumption on Vascular Endothelial Function
Vascular endothelial dysfunction contributes to a variety of cardiovascular and metabolic diseases. Despite anecdotal reports of adverse cardiovascular and hemodynamic effects of energy drink consumption there has been v...
Network Pharmacology and Traditional Chinese Medicine: Development of Anti-Diabetic Therapies
Partly due to the failure of single-target drugs, diabetes mellitus, a chronic metabolic disease with complex pathogenesis and long-term medication requirements, is increasing in prevalence worldwide and urgently needs m...
DKA in an Adolescent with Established Diagnosis of Type 1 Diabetes
Diabetic ketoacidosis (DKA) and its complications are the most common cause of hospitalization, morbidity and mortality in children and adolescents with established diagnosis of type 1 diabetes mellitus (T1DM). The overa...
Quantitative Models for Evaluating the Correlation between Baseline Hba1c Levels and Sitagliptin as Monotherapy or Dual Therapy Treatment in Type 2 Diabetes: A Meta-Regression Analysis
Aim: Baseline glycated hemoglobin (HbA1c) is critical in assessing anti-diabetic agent efficacy due to its ability to alter the response of HbA1c reduction to dipeptidyl peptidase-IV (DPP-IV) inhibitors. With meta-regres...